Division of Pediatric Gastroenterology and Nutrition, Mucosal Immunology and Biology Research Center, MassGeneral Hospital for Children, 175 Cambridge Street, CPZS - 574, Boston, MA 02114, USA; Celiac Research Program, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
Celiac Research Program, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA; Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.
Gastroenterol Clin North Am. 2019 Mar;48(1):145-163. doi: 10.1016/j.gtc.2018.09.011. Epub 2018 Dec 13.
Celiac disease (CD) is an autoimmune enteropathy triggered by gluten. Gluten-free diets can be challenging because of their restrictive nature, inadvertent cross-contaminations, and the high cost of gluten-free food. Novel nondietary therapies are at the preclinical stage, clinical trial phase, or have already been developed for other indications and are now being applied to CD. These therapies include enzymatic gluten degradation, binding and sequestration of gluten, restoration of epithelial tight junction barrier function, inhibition of tissue transglutaminase-mediated potentiation of gliadin oligopeptide immunogenicity or of human leukocyte antigen-mediated gliadin presentation, induction of tolerance to gluten, and antiinflammatory interventions.
乳糜泻（CD）是一种由麸质引发的自身免疫性肠病。由于其限制性质、无意中的交叉污染以及无麸质食品的高成本，无麸质饮食可能具有挑战性。新型非饮食疗法处于临床前阶段、临床试验阶段，或已针对其他适应症开发出来，并已应用于 CD。这些疗法包括酶解谷蛋白、谷蛋白的结合和隔离、上皮紧密连接屏障功能的恢复、抑制组织转谷氨酰胺酶介导的麦胶多肽免疫原性或人类白细胞抗原介导的麦胶呈递、诱导对谷蛋白的耐受性和抗炎干预。
